Takeda defeats sham litigation claims
Takeda Pharmaceuticals had a reasonable basis for alleging a generic drugmaker infringed upon its patented heartburn medication, a New Jersey federal court has said in finding the pharmaceutical company immune from allegations it illegally maintained a monopoly over Prevacid SoluTab.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10